Protagonist Therapeutics, Inc Research and Development Expense
Protagonist Therapeutics, Inc (PTGX) reported Research and Development Expense of $42.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-05
- Protagonist Therapeutics, Inc research and development expense for the quarter ending 2026-06-30 was $42.06M, a 13.57% increase year-over-year.
- Protagonist Therapeutics, Inc research and development expense for the quarter ending 2026-03-31 was $46.74M, a 30.22% increase year-over-year.
- Protagonist Therapeutics, Inc research and development expense for the quarter ending 2025-12-31 was $46.36M, a 32.82% increase year-over-year.
- Protagonist Therapeutics, Inc research and development expense for the quarter ending 2025-09-30 was $40.00M, a 11.21% increase year-over-year.
- Protagonist Therapeutics, Inc research and development expense for fiscal 2025 was $159.29M, a 15.32% increase from fiscal 2024.
- Protagonist Therapeutics, Inc research and development expense for fiscal 2024 was $138.13M, a 14.95% increase from fiscal 2023.
- Protagonist Therapeutics, Inc research and development expense for fiscal 2023 was $120.16M, a 4.80% decline from fiscal 2022.
- Protagonist Therapeutics, Inc research and development expense for fiscal 2022 was $126.22M, a 0.17% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $42.06M 10-Q · filed 2026-08-05 | $88.80M 10-Q · filed 2026-08-05 | $135.16M derived: sum of 3 quarters · filed 2026-08-05 | $175.16M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $46.74M 10-Q · filed 2026-05-05 | $93.10M derived: sum of 2 quarters · filed 2026-05-05 | $133.10M derived: sum of 3 quarters · filed 2026-05-05 | $170.14M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $46.36M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $86.36M derived: sum of 2 quarters · filed 2026-02-25 | $123.40M derived: sum of 3 quarters · filed 2026-08-05 | $159.29M 10-K · filed 2026-02-25 |
| 2025-09-30 | $40.00M 10-Q · filed 2025-11-06 | $77.04M derived: sum of 2 quarters · filed 2026-08-05 | $112.93M 10-Q · filed 2025-11-06 | $147.84M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $37.04M 10-Q · filed 2026-08-05 | $72.93M 10-Q · filed 2026-08-05 | $107.83M derived: sum of 3 quarters · filed 2026-08-05 | $143.80M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $35.89M 10-Q · filed 2026-05-05 | $70.80M derived: sum of 2 quarters · filed 2026-05-05 | $106.77M derived: sum of 3 quarters · filed 2026-05-05 | $140.29M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $34.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $70.87M derived: sum of 2 quarters · filed 2026-02-25 | $104.39M derived: sum of 3 quarters · filed 2026-02-25 | $138.13M 10-K · filed 2026-02-25 |
| 2024-09-30 | $35.97M 10-Q · filed 2025-11-06 | $69.49M derived: sum of 2 quarters · filed 2025-11-06 | $103.22M 10-Q · filed 2025-11-06 | $132.12M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $33.52M 10-Q · filed 2025-08-06 | $67.25M 10-Q · filed 2025-08-06 | $96.15M derived: sum of 3 quarters · filed 2026-02-25 | $126.82M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $33.73M 10-Q · filed 2025-05-06 | $62.63M derived: sum of 2 quarters · filed 2026-02-25 | $93.30M derived: sum of 3 quarters · filed 2026-02-25 | $126.48M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $28.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $59.56M derived: sum of 2 quarters · filed 2026-02-25 | $92.75M derived: sum of 3 quarters · filed 2026-02-25 | $120.16M 10-K · filed 2026-02-25 |
| 2023-09-30 | $30.66M 10-Q · filed 2024-11-07 | $63.85M derived: sum of 2 quarters · filed 2024-11-07 | $91.26M 10-Q · filed 2024-11-07 | $121.15M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | $33.18M 10-Q · filed 2024-08-06 | $60.60M 10-Q · filed 2024-08-06 | $90.48M derived: sum of 3 quarters · filed 2025-02-21 | $115.88M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | $27.42M 10-Q · filed 2024-05-07 | $57.30M derived: sum of 2 quarters · filed 2025-02-21 | $82.70M derived: sum of 3 quarters · filed 2025-02-21 | $117.31M derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $29.88M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $55.29M derived: sum of 2 quarters · filed 2025-02-21 | $89.90M derived: sum of 3 quarters · filed 2025-02-21 | $126.22M 10-K · filed 2025-02-21 |
| 2022-09-30 | $25.40M 10-Q · filed 2023-11-02 | $60.01M derived: sum of 2 quarters · filed 2023-11-02 | $96.33M 10-Q · filed 2023-11-02 | $134.70M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $34.61M 10-Q · filed 2023-08-03 | $70.93M 10-Q · filed 2023-08-03 | $109.30M derived: sum of 3 quarters · filed 2024-02-27 | $146.26M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $36.32M 10-Q · filed 2023-05-04 | $74.69M derived: sum of 2 quarters · filed 2024-02-27 | $111.65M derived: sum of 3 quarters · filed 2024-02-27 | $138.08M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $38.37M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $75.33M derived: sum of 2 quarters · filed 2024-02-27 | $101.76M derived: sum of 3 quarters · filed 2024-02-27 | $126.01M 10-K · filed 2024-02-27 |
| 2021-09-30 | $36.96M 10-Q · filed 2022-11-08 | $63.39M derived: sum of 2 quarters · filed 2022-11-08 | $87.63M 10-Q · filed 2022-11-08 | $107.12M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $26.43M 10-Q · filed 2022-08-04 | $50.68M 10-Q · filed 2022-08-04 | $70.16M derived: sum of 3 quarters · filed 2023-03-15 | $86.16M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $24.25M 10-Q · filed 2022-05-05 | $43.73M derived: sum of 2 quarters · filed 2023-03-15 | $59.73M derived: sum of 3 quarters · filed 2023-03-15 | $79.98M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $19.49M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $35.48M derived: sum of 2 quarters · filed 2023-03-15 | $55.74M derived: sum of 3 quarters · filed 2023-03-15 | $74.51M 10-K · filed 2023-03-15 |
| 2020-09-30 | $15.99M 10-Q · filed 2021-11-03 | $36.25M derived: sum of 2 quarters · filed 2021-11-03 | $55.02M 10-Q · filed 2021-11-03 | $70.93M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $20.26M 10-Q · filed 2021-08-04 | $39.02M 10-Q · filed 2021-08-04 | $54.94M derived: sum of 3 quarters · filed 2022-02-28 | $72.23M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $18.77M 10-Q · filed 2021-05-04 | $34.68M derived: sum of 2 quarters · filed 2022-02-28 | $51.97M derived: sum of 3 quarters · filed 2022-02-28 | $71.33M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $15.91M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $33.20M derived: sum of 2 quarters · filed 2022-02-28 | $52.56M derived: sum of 3 quarters · filed 2022-02-28 | $65.00M 10-K · filed 2022-02-28 |
| 2019-09-30 | $17.29M 10-Q · filed 2020-11-04 | $36.65M derived: sum of 2 quarters · filed 2020-11-04 | $49.09M 10-Q · filed 2020-11-04 | $63.34M derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-06-30 | $19.36M 10-Q · filed 2020-08-06 | $31.80M 10-Q · filed 2020-08-06 | $46.05M derived: sum of 3 quarters · filed 2021-03-10 | $58.19M derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-03-31 | $12.44M 10-Q · filed 2020-05-07 | $26.69M derived: sum of 2 quarters · filed 2021-03-10 | $38.84M derived: sum of 3 quarters · filed 2021-03-10 | $56.57M derived: sum of 4 quarters · filed 2021-03-10 |
| 2018-12-31 | $14.25M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | $26.39M derived: sum of 2 quarters · filed 2021-03-10 | $44.13M derived: sum of 3 quarters · filed 2021-03-10 | $59.50M 10-K · filed 2021-03-10 |
| 2018-09-30 | $12.14M 10-Q · filed 2019-11-06 | $29.88M derived: sum of 2 quarters · filed 2019-11-06 | $45.25M 10-Q · filed 2019-11-06 | $56.97M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-06-30 | $17.73M 10-Q · filed 2019-08-07 | $33.10M 10-Q · filed 2019-08-07 | $44.83M derived: sum of 3 quarters · filed 2020-03-10 | $55.99M derived: sum of 4 quarters · filed 2020-03-10 |
| 2018-03-31 | $15.37M 10-Q · filed 2019-05-08 | $27.09M derived: sum of 2 quarters · filed 2020-03-10 | $38.26M derived: sum of 3 quarters · filed 2020-03-10 | $50.27M derived: sum of 4 quarters · filed 2020-03-10 |
| 2017-12-31 | $11.72M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $22.89M derived: sum of 2 quarters · filed 2020-03-10 | $34.90M derived: sum of 3 quarters · filed 2020-03-10 | $46.18M 10-K · filed 2020-03-10 |
| 2017-09-30 | $11.17M 10-Q · filed 2018-11-06 | $23.18M derived: sum of 2 quarters · filed 2018-11-06 | $34.46M 10-Q · filed 2018-11-06 | $43.28M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-06-30 | $12.01M 10-Q · filed 2018-08-07 | $23.29M 10-Q · filed 2018-08-07 | $32.11M derived: sum of 3 quarters · filed 2019-03-12 | $37.67M derived: sum of 4 quarters · filed 2019-03-12 |
| 2017-03-31 | $11.28M 10-Q · filed 2018-05-09 | $20.11M derived: sum of 2 quarters · filed 2019-03-12 | $25.67M derived: sum of 3 quarters · filed 2019-03-12 | $31.36M derived: sum of 4 quarters · filed 2019-03-12 |
| 2016-12-31 | $8.82M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $14.38M derived: sum of 2 quarters · filed 2019-03-12 | $20.08M derived: sum of 3 quarters · filed 2019-03-12 | $25.70M 10-K · filed 2019-03-12 |
| 2016-09-30 | $5.56M 10-Q · filed 2017-11-07 | $11.26M derived: sum of 2 quarters · filed 2017-11-07 | $16.88M 10-Q · filed 2017-11-07 | $21.07M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | $5.70M 10-Q · filed 2017-08-08 | $11.32M 10-Q · filed 2017-08-08 | $15.51M derived: sum of 3 quarters · filed 2018-03-07 | $18.67M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | $5.63M 10-Q · filed 2017-05-10 | $9.82M derived: sum of 2 quarters · filed 2018-03-07 | $12.98M derived: sum of 3 quarters · filed 2018-03-07 | $15.27M derived: sum of 4 quarters · filed 2018-03-07 |
| 2015-12-31 | $4.19M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $7.35M derived: sum of 2 quarters · filed 2018-03-07 | $9.65M derived: sum of 3 quarters · filed 2018-03-07 | $11.83M 10-K · filed 2018-03-07 |
| 2015-09-30 | $3.16M 10-Q · filed 2016-11-14 | $5.46M derived: sum of 2 quarters · filed 2016-11-14 | $7.64M 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $2.30M 10-Q · filed 2016-09-15 | $4.48M 10-Q · filed 2016-09-15 | ||
| 2014-12-31 | $7.46M 10-K · filed 2017-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |